Table 3.

General pharmacological screening of compound 7b and milrinone (M).

Test	Dose (mg/kg) or Conc. (μg/mL)	Considered parameter	Significant criterion	7b	M	Additional reference druga
MTD and Irwin testb	p.o. 300	Number animals (died/treated)		3/3	nt
	100			3/3	3/3 (48h)
	30			0/3	3/3 (48h)
	i.p. 100			3/3	3/3
	50			nt	3/3 (24h)
	30			0/3	3/3 (48h)
Blood pressure	p.o. 30	Δ% after 1 and 4 h	>10%	−4/0	nt
	10				−13/13
	5				−3/−3
Heart rate	p.o. 30	Δ% after 1 and 4 h	>20%	+3/+5	+7/+8
CHCl3 arrhythmia	i.p. 30	N° protected animals/treated		1/3		Lidocaine: 3/3
	5		>1/3		0/3	Quinidine (100 mg/kg): 3/3
Inotropismc (in vitro)	10	Δ%	>40%	+56	+72	Trequinsin: +48
	3			+31	+60
	0.5				+45
Chronotropism (in vitro)	10	Δ%	>10	−23	nt	Quinidine: −20; mecamylamine: −14
	5				+11
	3			−10
	2.5				+7
	1			−3
Saluresis	p.o. 30	Urine Na+ μeq treated/control	>2	4.5		Furosemide (5 mg/kg): 3.0 Triamterene (2.5 mg/kg): 2.6
	10			4.1	0.5
	3			3.4
Diuresis	p.o. 30	Urine vol. treated/control	>1.5	2.2	nt	Amiloride (20 mg/kg): 1.6 Hydroflumethiazide (2.5 mg/kg): 1.7
	10			2.0	0.4
	3			1.8
Tracheal contractile tension (in vitro)	100	Relaxation (%)	>50%	nt	100
	30			16	nt	Theophylline: 60
	1.0			nt	50
	0.5			nt	23
Anti-inflammatory (paw edema)	p.o. 100	Inhibition (%)	>30%	42	nt	Aspirin (150 mg/kg): 40 Phenylbutazone (50 mg/kg): 33 Hydrocortisone (25 mg/kg): 32
	30			34	nt
	10			0	20
Phenylquinone writhing	p.o. 300	Writhing inhibition (%)	>50%	nt	42	Aspirin (50 mg/kg): 68
	30			60	nt
	10			20	nt
Formalin algesia	p.o. 30	Licking time reduction (%)	>50%	89	ntd
	10			27

nt: not tested.

^aWhen not otherwise specified, the drug reference dosage corresponds to that of column 2.

^bMTD: maximal tolerated dose; neither significant motor stimulation nor behavioral depression were observed.

^cNot blocked by propranolol.

^dOnly compounds active in the writhing test were assayed.